Swiss oncology giant Roche (ROG: SIX) has announced an extension to the US review of its risdiplam New Drug Application (NDA) in spinal muscular atrophy (SMA).
A decision is now expected three months later, by August 24, due to the recent submission of additional data, including data from the pivotal SUNFISH Part II study.
One-year data from SUNFISH Part II showed that change from baseline in a commonly-used motor function scale was significantly greater for the risdiplam group, compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze